Effect of Diltiazem on Pharmacokinetics of BMS-914392

Completed · Phase 1

Conditions studied: Atrial Fibrillation

In brief

The purpose of this study is to assess the effects of diltiazem on the pharmacokinetics of single-dose BMS-914392 in healthy subjects.

Key facts

Study ID

NCT01211808

Run by

Bristol-Myers Squibb

People needed

24

Starts

2010-09-01

Expected to finish

2010-10-01

Last updated by the study team

2011-02-02

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy

You may not qualify if…

• Current or recent (within 3 months of study drug administration) gastrointestinal disease
• Current or history of neurological diseases or psychiatric disorders and cardiovascular diseases

Where it is running

• Pra International — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.